Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Semaglutide Kidney Mechanism Trial
A randomized kidney study found negative primary MRI outcomes but secondary vascular and tissue signals that may explain semaglutide's effects.
Semaglutide MicroRNA Pilot Study
A 31-person semaglutide pilot found eight nominal microRNA changes, but none remained significant after correcting for multiple tests.
Weight Loss and Sleep Apnea: 2026 Review
A 2026 review links obesity treatment with better sleep-apnea measures. We separate its conclusions from the randomized tirzepatide evidence.
Pediatric GLP-1 Review: Effects and Safety
A 2026 systematic review links pediatric GLP-1 medicines with lower BMI or HbA1c, while highlighting gastrointestinal effects and long-term gaps.
Tirzepatide vs semaglutide: indirect data
A 2026 analysis compared SURMOUNT-1 with STEP 1. Tirzepatide 10 mg and 15 mg were associated with greater weight reduction, but this was not a new trial.
TRIUMPH-2: Retatrutide at 80 Weeks
TRIUMPH-2 found greater weight loss with retatrutide than placebo at 80 weeks in adults with obesity and type 2 diabetes.
Tirzepatide lean-mass review
A 2026 review found that tirzepatide weight loss mostly came from fat, but lean mass also fell and muscle function was not measured.
Semaglutide and taste in mice
A 2026 mouse study found preserved taste responses during chronic semaglutide treatment, despite changes in sucrose-directed behavior.
A two-timepoint semaglutide brain map
A mouse study mapped semaglutide-linked activity across more than 500 brain areas using two timepoints, finding 24 engaged regions.
Surgery vs semaglutide and tirzepatide
A 44,025-person record study associated bariatric surgery with more weight loss than semaglutide or tirzepatide, but it was not randomized.
Tirzepatide response after eight weeks
A SURMOUNT post hoc analysis linked early tirzepatide weight response with larger 72-week changes, while later responders still lost weight.
Adolescent GLP-1 use: what remains unknown
A 2026 commentary reviews skeletal, reproductive and psychosocial questions around semaglutide and other GLP-1 drugs in adolescents.